Opioid Use Disorder

Opioid Use Disorder is a problematic pattern of opioid use, encompassing prescription pain medications, illicit opioids like heroin, and increasingly dangerous synthetic opioids like fentanyl, leading to clinically significant impairment or distress. It is one of the most medically dangerous substance use disorders given its high overdose risk, and represents a major public health crisis in many parts of the world.

Opioid Use Disorder is a problematic pattern of opioid use leading to clinically significant impairment or distress, manifested by two or more of eleven criteria within a 12-month period. Notably, tolerance and withdrawal are not counted toward the diagnosis when opioids are taken solely under appropriate medical supervision as prescribed, to avoid pathologizing expected physiological adaptation during legitimate pain treatment.

Opioids act on mu-opioid receptors, producing powerful analgesic and euphoric effects with a high potential for both physical dependence and psychological addiction. The disorder often begins with a legitimate prescription for pain management that progresses to misuse, or with illicit use directly. The opioid crisis in many countries has been significantly driven by historical aggressive marketing and overprescription of prescription opioids, alongside the emergence of highly potent, dangerous illicit synthetic opioids like fentanyl.

• Prior history of substance use disorder
• Chronic pain conditions requiring long-term opioid prescription
• Family history of substance use disorders
• Co-occurring mental health conditions
• History of trauma
• Easy access to prescription opioids
• Exposure to illicit opioid markets

Opioids bind to mu-opioid receptors throughout the brain and body, producing analgesia and a powerful euphoric reward signal via dopamine release in the mesolimbic pathway. With repeated use, the brain adapts by reducing natural endorphin production and receptor sensitivity, producing tolerance and a severe withdrawal syndrome when opioids are stopped. The noradrenergic locus coeruleus system becomes hyperactive during withdrawal, driving many of the characteristic withdrawal symptoms.

• Strong cravings for opioids
• Unsuccessful efforts to cut down or control use
• Significant time spent obtaining, using, or recovering from opioids
• Tolerance
• Withdrawal symptoms when stopping — muscle aches, sweating, anxiety, insomnia, nausea, vomiting, diarrhea, dilated pupils, goosebumps
• Continued use despite awareness of physical or psychological harm
• Failure to fulfill major role obligations
• Giving up important activities in favor of use
• Recurrent use in physically hazardous situations

• Two or more of eleven criteria within a 12-month period (tolerance/withdrawal excluded if occurring solely under appropriate medical supervision as prescribed)
• Causes significant distress or impairment
• Severity specified as mild, moderate, or severe

Conditions a psychiatrist will consider and rule out before confirming this diagnosis:

Appropriate medical opioid use for pain management

Physical dependence alone, expected with prescribed long-term opioid use, is not equivalent to opioid use disorder unless the broader behavioral criteria are also met.

Other substance use disorders

Frequently co-occur.

Chronic pain requiring carefully monitored opioid management

Requires careful clinical distinction, often with specialist pain management involvement.

• Clinical interview and detailed substance use history
• Prescription drug monitoring program review where available
• Urine toxicology screening
• Screening tools such as the Opioid Risk Tool for those being considered for prescription opioid therapy
• Screening for co-occurring substance use and psychiatric conditions
• Hepatitis C and HIV screening where injection drug use risk is relevant

Medication for Opioid Use Disorder (MOUD) — buprenorphine, methadone, or naltrexone — combined with psychosocial support is the evidence-based standard of care and significantly reduces overdose mortality compared to non-medication approaches. Harm reduction measures, particularly naloxone distribution for overdose reversal, are a critical component of a comprehensive response.

Buprenorphine

A partial opioid agonist reducing cravings and withdrawal, with a ceiling effect limiting overdose risk compared to full agonists.

Methadone

A full opioid agonist provided through regulated treatment programs, highly effective at reducing illicit use and overdose risk.

Naltrexone

An opioid antagonist blocking the effects of opioids, used for relapse prevention after safe completion of detoxification.

Naloxone

An opioid overdose reversal medication that should be available to anyone at risk of opioid overdose or their close contacts.

Contingency management

Strong evidence, particularly in combination with medication treatment.

Cognitive Behavioral Therapy

For relapse prevention.

Motivational Interviewing

Builds engagement with treatment.

12-step facilitation / mutual support groups

Peer support programs.

Family therapy

Given the significant impact on family systems.

• Engage consistently with medication for opioid use disorder rather than attempting abstinence-only approaches, which carry substantially higher overdose risk
• Have naloxone available and ensure close contacts know how to use it
• Avoid using alone, given overdose risk
• Build a support network
• Address co-occurring chronic pain through comprehensive, multimodal pain management where possible

Opioid Use Disorder is a chronic, relapsing condition, but medication-assisted treatment significantly improves outcomes, including reduced illicit use, reduced overdose mortality, and improved overall functioning. Without treatment, or with abstinence-only approaches lacking medication support, relapse and overdose risk remain very high, particularly given reduced tolerance after a period of abstinence.

• Cautious, judicious opioid prescribing practices with careful risk assessment
• Prescription drug monitoring programs
• Widespread naloxone availability and training
• Harm reduction services
• Early treatment of pain and psychiatric conditions to reduce risk of progression to opioid misuse

Understand Opioid Use Disorder as a chronic medical condition with a high risk of fatal overdose, making harm reduction and naloxone access a critical priority regardless of views on abstinence. Support engagement with medication treatment rather than viewing it as 'just replacing one drug with another' — it is an evidence-based, life-saving treatment. Understand relapse as a common part of the chronic disease course, and have naloxone available at home.

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision (DSM-5-TR).
2. Substance Abuse and Mental Health Services Administration (SAMHSA).
3. Centers for Disease Control and Prevention (CDC). Opioid overdose prevention resources.